Benefits, Barriers, and Challenges to Using Proton Therapy for Cancer Treatment

Video

This video reviews the benefits of proton therapy and some of the barriers and challenges preventing the integration of the technology into regular practice.

In this video, Zhongxing Liao, MD, of MD Anderson Cancer Center in Houston, Texas, discusses the benefits of proton therapy and talks about some of the barriers and challenges-such as treatment planning, costs, and insurance reimbursement-preventing the integration of the technology into regular practice.

Liao gave a presentation on this topic earlier this year at the 2017 Multidisciplinary Thoracic Cancers Symposium.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

FDA Grants Breakthrough Therapy Status to Ziftomenib in R/R NPM1+ AML | Image Credit: © LASZLO - stock.adobe.com.

FDA Grants Breakthrough Therapy Status to Ziftomenib in R/R NPM1+ AML

April 24th 2024
Article

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer

April 23rd 2024
Article

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.